$11,514.97 consulting Payment -- Eli Lilly and Company to Dr. Kevin Hill

Psychiatrist Receives Over $11,000 Consulting Fee from Eli Lilly for Ozempic-Related Services

This page provides a detailed analysis of a $11,514.97 consulting payment from Eli Lilly and Company to Dr. Kevin Hill. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$11,514.97
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyEli Lilly and Company
PhysicianDr. Kevin Hill
NPI Number1153749672
Physician SpecialtyPsychiatry
LocationCity, VA
Date of Payment2024-05-25
Related Drug/DeviceOzempic
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Eli Lilly and Company made a $11.5K consulting payment to Kevin Hill, a Psychiatry specialist in City, VA. The payment was associated with Ozempic. The payment of $11,514.97 to Dr. Kevin Hill from Eli Lilly and Company for consulting services is a significant amount for a single payment. The payment is associated with Ozempic, a drug used for diabetes and weight management, which aligns with Psychiatry as a specialty. The payment was made on May 25, 2024, indicating a recent engagement between the physician and the pharmaceutical company.

Patient Guidance: What This Payment Means for You

If you are a patient, this payment indicates your doctor may be providing expert advice to pharmaceutical companies, which is a common practice in medical research and development. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

While consulting fees are common in Psychiatry, an $11,514.97 payment for a single consulting engagement is on the higher end compared to typical speaker fees or advisory board stipends.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $11.5K payment for?

This was a consulting payment of $11.5K from Eli Lilly and Company to Kevin Hill, categorized as "Consulting Fee". It was associated with Ozempic. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Kevin Hill accept pharmaceutical money?

Yes, Kevin Hill received this $11.5K payment from Eli Lilly and Company. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Kevin Hill's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $11.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Psychiatry?

To compare this payment against Psychiatry averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Psychiatry physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Kevin Hill's relationship with Eli Lilly and Company?

The payment is categorized as a 'Consulting Fee', suggesting Dr. Hill provided expert advice or services. This $11.5K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Psychiatry?

The amount is substantial, potentially indicating a long-term or high-value consulting arrangement.

What should patients do after learning about this payment?

If you are a patient, this payment indicates your doctor may be providing expert advice to pharmaceutical companies, which is a common practice in medical research and development.

What else should I know about this consulting payment?

The specific drug mentioned, Ozempic, is relevant to conditions often managed within Psychiatry, such as comorbid depression or anxiety with metabolic disorders.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.